Holen Sie sich die Stockscreener-App
85.94
1.88%
-1.65
Schlusskurs vom Vortag:
$87.59
Offen:
$86.97
24-Stunden-Volumen:
197.32K
Relative Volume:
1.54
Marktkapitalisierung:
$3.93B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.75%
1M Leistung:
-21.54%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$83.30
$88.49
1-Wochen-Bereich:
$83.30
$100.00
52-Wochen-Spanne:
$80.51
$138.70
Billiontoone Inc Stock (BLLN) Company Profile
Firmenname
Billiontoone Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLLN
Billiontoone Inc
|
85.94 | 4.01B | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Billiontoone Inc Stock (BLLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Eingeleitet | Guggenheim | Buy |
| 2025-12-01 | Eingeleitet | BTIG Research | Buy |
| 2025-12-01 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-01 | Eingeleitet | Jefferies | Hold |
| 2025-12-01 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-01 | Eingeleitet | Stifel | Buy |
| 2025-12-01 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Billiontoone Inc Aktie (BLLN) Neueste Nachrichten
January 2026's Top Growth Companies With Insider Confidence - Yahoo Finance
BillionToOne, Inc. Announces Selection of Northstar Select as New Liquid Biopsy Test for LC-SCRUM-TRY Clinical Study at National Cancer Center Hospital East - MarketScreener
BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East - PR Newswire
3 Stocks Estimated To Be Up To 48.4% Below Intrinsic Value - Yahoo Finance
BillionToOne (BLLN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
BillionToOne Earnings Notes - Trefis
Med-tech IPOs shoot for the stars in 2025 - BioWorld MedTech
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference - 富途牛牛
BillionToOne stock in focus before Monday open after Friday jump, JPMorgan conference next - ts2.tech
BillionToOne (BLLN) Stock Update: Friday Rally, Analyst Price Targets, and the Next Catalysts Before Nasdaq Reopens - ts2.tech
BillionToOne Stock (NASDAQ: BLLN) News: Weekend Market Wrap, Analyst Targets, and What to Watch Before Monday’s Open - TechStock²
BillionToOne Stock (NASDAQ: BLLN) Rises Into the Weekend as Analyst Targets Point Higher — What Investors Need to Know Before Monday - ts2.tech
Should I buy BillionToOne, Inc. (BLLN) - Zacks Investment Research
Evommune and BillionToOne climb on trading debut - MSN
BillionToOne (BLLN) Is Down 6.7% After Joining the S&P Total Market IndexWhat's Changed - simplywall.st
BillionToOne falls -5.5% - MSN
BillionToOne: An Interesting Set-Up Into 2026 - Seeking Alpha
BillionToOne Stock (NASDAQ: BLLN) News, Forecasts, and Analyst Outlook for December 22, 2025 - ts2.tech
BillionToOne Adds Genmab CFO Anthony Pagano to Board, Names Him Audit Chair - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), BillionToOne, Inc. Class A (BLLN) - The Globe and Mail
BillionToOne’s Earnings Call: Strong Growth and Strategic Outlook - TipRanks
BillionToOne, Inc. (NASDAQ:BLLN) Q3 2025 earnings call transcript - MSN
symbol__ Stock Quote Price and Forecast - CNN
Transcript : BillionToOne, Inc., Q3 2025 Earnings Call, Dec 09, 2025 - marketscreener.com
November reignites med-tech momentum with $4.7B raised - BioWorld MedTech
These Bay Area companies are IPO contenders in 2026 - The Business Journals
BillionToOne, Inc.: Strong Financial Performance and Strategic Market Positioning Drive Buy Rating - TipRanks
BillionToOne (BLLN) Revenue Surge Tests Bullish Growth Narrative Despite Ongoing EPS Losses - Sahm
BillionToOne, Inc.: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating - TipRanks
BillionToOne, Inc. SEC 10-Q Report - TradingView — Track All Markets
BillionToOne price target lowered to $145 from $150 at JPMorgan - MSN
BillionToOne stock rating reiterated at Overweight by Piper Sandler - Investing.com South Africa
Jim Cramer Says BillionToOne Has a “Fantastic Story” Within the Diagnostics Space - MSN
BillionToOne Swings To Profit In Q3; Sees Q4 Revenue Soaring Up To 100% - Nasdaq
BillionToOne’s Strong Growth Potential and Strategic Integration Drive Buy Rating - TipRanks
BTIG Reiterates 'Buy' Rating for BillionToOne (BLLN) with PT of $160 | BLLN Stock News - GuruFocus
Earnings call transcript: BillionToOne’s strong Q3 2025 lifts stock 3.19% By Investing.com - Investing.com Nigeria
Billiontoone Q3 2025 Earnings Call Transcript - MarketBeat
BillionToOne Q3 2025 presentation slides: Revenue soars 117% as profitability achieved - Investing.com Canada
Earnings call transcript: BillionToOne’s strong Q3 2025 lifts stock 3.19% - Investing.com
Earnings call transcript: BillionToOne's strong Q3 2025 lifts stock 3.19% - Investing.com
BillionToOne appoints Genmab CFO Anthony Pagano to board - Investing.com
BillionToOne sees Q4 revenue $84M-$90M, consensus $80.14M - TipRanks
BillionToOne Appoints Anthony Pagano as Audit Chair - TipRanks
BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours - marketscreener.com
Finanzdaten der Billiontoone Inc-Aktie (BLLN)
Es liegen keine Finanzdaten für Billiontoone Inc (BLLN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):